Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Oncotarget|February 22, 2018
Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapySeung-Hwan Shin, Byung-Sik Cho, Sung-Soo Park, et al.
Scientific Reports|October 15, 2023
The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphomaGi-June Min, Young-Woo Jeon, Tong Yoon Kim, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 10, 2018
Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center ReportSung-Soo Park, Hee-Je Kim, Kyoung Il Min, et al.
Frontiers in Oncology|August 22, 2022
Long-term treatment outcome of Castleman's disease: A real-world experienceGi-June Min, Young-Woo Jeon, Tong Yoon Kim, et al.
Cancers|January 22, 2021
Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1Byung-Sik Cho, Gi-June Min, Sung-Soo Park, et al.
Bone Marrow Transplantation|March 4, 2024
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1Silvia Park, Su-Yeon Bang, Daehun Kwag, et al.
Cancers|July 9, 2022
Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk StratificationTong-Yoon Kim, Silvia Park, Daehun Kwag, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromesJae-Ho Yoon, Young-Woo Jeon, Seung-Ah Yahng, et al.
Therapeutic Advances in Hematology|March 28, 2022
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)Silvia Park, Daehun Kwag, Tong Yoon Kim, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Pageof 13